CytoSorbents Corporation (CTSO)

[pharmeng]

That's unfortunate because a trial with a few hundred patients is not that many. A lot of phase 2b studies are 200-300 patients. Might as well go big or go home, and run the trial. The trial could have been done by now if they started it after receiving CE mark. 28 day endpoint is a very fast endpoint.

What do you think the market of cardiac surgery will be? If intraoperative, I'd guess they use one filter. Q2 transcript mentioned US/EU market is ~1 million surgeries per year, so sales in the few hundred million range at peak sales for US/EU. I am also curious as to how receptive reimbursement is if only a biomarker is used as primary endpoint. Seems ok in the EU so far, which is interesting given they seem to drive a harder bargain for reimbursement than US. Cardiac surgery approval will be great, but I still hope that it can be proven to be effective in sepsis.